Search details
1.
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
Cancer
; 130(7): 1061-1071, 2024 04 01.
Article
in English
| MEDLINE | ID: mdl-38009662
2.
The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
Br J Cancer
; 130(11): 1875-1884, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38582811
3.
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Gynecol Oncol
; 186: 42-52, 2024 Apr 05.
Article
in English
| MEDLINE | ID: mdl-38582027
4.
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol
; 186: 61-68, 2024 Apr 10.
Article
in English
| MEDLINE | ID: mdl-38603953
5.
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
Am J Obstet Gynecol
; 230(5): 544.e1-544.e13, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38191019
6.
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Lancet
; 399(10324): 541-553, 2022 02 05.
Article
in English
| MEDLINE | ID: mdl-35123694
7.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol
; 174: 213-223, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37229879
8.
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Gynecol Oncol
; 173: 130-137, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37148580
9.
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors.
Am J Obstet Gynecol
; 228(6): 724.e1-724.e9, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36907533
10.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer
; 33(9): 1331-1344, 2023 09 04.
Article
in English
| MEDLINE | ID: mdl-37591609
11.
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
J Transl Med
; 20(1): 606, 2022 12 17.
Article
in English
| MEDLINE | ID: mdl-36528667
12.
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gynecol Oncol
; 167(2): 139-145, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36137845
13.
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gynecol Oncol
; 165(3): 560-567, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35606067
14.
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Gynecol Oncol
; 167(3): 423-428, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36244829
15.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
J Natl Compr Canc Netw
; 20(9): 972-980, 2022 09.
Article
in English
| MEDLINE | ID: mdl-36075393
16.
Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
Gynecol Oncol
; 162(3): 728-734, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34238613
17.
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(2): 191-226, 2021 02 02.
Article
in English
| MEDLINE | ID: mdl-33545690
18.
Fertility preservation in rare ovarian tumors.
Int J Gynecol Cancer
; 31(3): 432-441, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33649010
19.
Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
Gynecol Oncol
; 157(1): 21-28, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31954535
20.
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Gynecol Oncol
; 158(3): 653-658, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32709538